Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 327852 | 4.99 |
09:34 ET | 107327 | 5.0188 |
09:36 ET | 56324 | 5 |
09:38 ET | 170105 | 5.08 |
09:39 ET | 126326 | 5.0102 |
09:41 ET | 132716 | 5.03 |
09:43 ET | 51599 | 5.03 |
09:45 ET | 39916 | 5.025 |
09:48 ET | 85676 | 5.04 |
09:50 ET | 56077 | 5.02 |
09:52 ET | 39223 | 5.0301 |
09:54 ET | 76664 | 5.01 |
09:56 ET | 114436 | 5.002 |
09:57 ET | 121166 | 5.035 |
09:59 ET | 161379 | 5.046 |
10:01 ET | 318148 | 5.095 |
10:03 ET | 75574 | 5.1 |
10:06 ET | 73088 | 5.1155 |
10:08 ET | 64886 | 5.118 |
10:10 ET | 50418 | 5.1111 |
10:12 ET | 164604 | 5.1 |
10:14 ET | 44530 | 5.125 |
10:15 ET | 76665 | 5.115 |
10:17 ET | 40704 | 5.138 |
10:19 ET | 338608 | 5.17 |
10:21 ET | 120729 | 5.13 |
10:24 ET | 54800 | 5.15 |
10:26 ET | 29624 | 5.15 |
10:28 ET | 354517 | 5.2 |
10:30 ET | 95126 | 5.205 |
10:32 ET | 62689 | 5.2 |
10:33 ET | 249632 | 5.22 |
10:35 ET | 117930 | 5.23 |
10:37 ET | 120136 | 5.22 |
10:39 ET | 327265 | 5.26 |
10:42 ET | 160729 | 5.2364 |
10:44 ET | 129447 | 5.215 |
10:46 ET | 95760 | 5.22 |
10:48 ET | 174767 | 5.23 |
10:50 ET | 51877 | 5.25 |
10:51 ET | 205125 | 5.265 |
10:53 ET | 186782 | 5.2512 |
10:55 ET | 144769 | 5.275 |
10:57 ET | 156141 | 5.2788 |
11:00 ET | 159117 | 5.295 |
11:02 ET | 297025 | 5.31 |
11:04 ET | 152036 | 5.3076 |
11:06 ET | 265510 | 5.3 |
11:08 ET | 68285 | 5.285 |
11:09 ET | 250623 | 5.27 |
11:11 ET | 278854 | 5.255 |
11:13 ET | 190792 | 5.23 |
11:15 ET | 250045 | 5.2264 |
11:18 ET | 145429 | 5.25 |
11:20 ET | 128057 | 5.2603 |
11:22 ET | 82342 | 5.26 |
11:24 ET | 21153 | 5.265 |
11:26 ET | 144115 | 5.26 |
11:27 ET | 81802 | 5.2696 |
11:29 ET | 51746 | 5.2601 |
11:31 ET | 40077 | 5.26 |
11:33 ET | 263584 | 5.235 |
11:36 ET | 23778 | 5.235 |
11:38 ET | 92595 | 5.235 |
11:40 ET | 116952 | 5.205 |
11:42 ET | 34182 | 5.235 |
11:44 ET | 83420 | 5.2402 |
11:45 ET | 14206 | 5.245 |
11:47 ET | 63010 | 5.23 |
11:49 ET | 21037 | 5.235 |
11:51 ET | 20087 | 5.24 |
11:54 ET | 128347 | 5.255 |
11:56 ET | 19801 | 5.26 |
11:58 ET | 24696 | 5.275 |
12:00 ET | 33155 | 5.25 |
12:02 ET | 40833 | 5.28 |
12:03 ET | 32012 | 5.287 |
12:05 ET | 92138 | 5.285 |
12:07 ET | 57398 | 5.28 |
12:09 ET | 34503 | 5.275 |
12:12 ET | 13805 | 5.28 |
12:14 ET | 12326 | 5.285 |
12:16 ET | 34174 | 5.29 |
12:18 ET | 76043 | 5.27 |
12:20 ET | 8824 | 5.275 |
12:21 ET | 65367 | 5.2401 |
12:23 ET | 101905 | 5.255 |
12:25 ET | 74466 | 5.2548 |
12:27 ET | 114634 | 5.255 |
12:30 ET | 10567 | 5.255 |
12:32 ET | 56999 | 5.26 |
12:34 ET | 111741 | 5.295 |
12:36 ET | 52948 | 5.3 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -15.3x | --- |
MoonLake Immunotherapeutics | 2.7B | -58.4x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.9x | --- |
Agios Pharmaceuticals Inc | 2.7B | -7.5x | --- |
Avidity Biosciences Inc | 2.5B | -9.4x | --- |
Biohaven Ltd | 3.0B | -5.1x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -15.3x |
Price/Sales (TTM) | 5,235.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.